Therapeutic Asset Ratings

515 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Cotadutide Type 2 Diabetes Mellitus	AstraZeneca	P2	BBB (78)
Mirvetuximab Soravtansine Epithelial Ovarian Cancer	AstraZeneca	P3	BBB (76)
Posaconazole Acute Myelogenous Leukemia	AstraZeneca	P4	BBB (74)
Irinotecan Esophagogastric Junction Carcinoma	AstraZeneca	P3	BBB (74)
PREDNISONE TABLETS Small Lymphocytic Lymphoma	AstraZeneca	P3	BBB (72)
Carboplatin Carcinoma	AstraZeneca	P4	BB (71)
Capivasertib Triple Negative Breast Neoplasms	AstraZeneca	P3	BB (71)
CIS-DIAMMINEDICHLOROPLATINUM II Advanced Pleural Malignant Mesothelioma	AstraZeneca	P2	BB (71)
Abiraterone Acetate Castration-resistant Prostate Cancer	AstraZeneca	P4	BB (69)
CABAZITAXEL Metastatic Castration-resistant Prostate Cancer	AstraZeneca	P4	BB (68)
Camizestrant Advanced Breast Cancer	AstraZeneca	P3	BB (68)
Inno-206 Small Lymphocytic Lymphoma	AstraZeneca	P3	BB (68)
Irinotecan Lung Adenocarcinoma	AstraZeneca	P3	BB (68)
Apalutamide Metastatic Prostate Cancer	AstraZeneca	P4	BB (67)
Enzalutamide Metastatic Castration-resistant Prostate Cancer	AstraZeneca	P4	BB (67)
Irinotecan Gastroesophageal Junction Adenocarcinoma	AstraZeneca	P3	BB (67)
(+)-VINCRISTINE Lung Adenocarcinoma	AstraZeneca	P3	BB (67)
(+)-VINCRISTINE Small Lymphocytic Lymphoma	AstraZeneca	P3	BB (67)
azd6234 Obesity or Overweight	AstraZeneca	P2	BB (67)
Carboplatin Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma	AstraZeneca	P2	BB (67)
Cotadutide Non-alcoholic Steatohepatitis	AstraZeneca	P2	BB (67)
azd5305 Metastatic Castration-Sensitive Prostate Cancer	AstraZeneca	P3	BB (66)
AZD9291 Advanced Non Small Cell Lung Cancer	AstraZeneca	P3	BB (66)
FLUOROURACILUM Esophageal Squamous Cell Cancer	AstraZeneca	P3	BB (66)
Inno-206 Endometrial Cancer	AstraZeneca	P3	BB (66)

Showing 1 to 25 of 515 assets

PreviousPage 1 of 21Next